NEW YORK and LONDON, Oct. 30 /PRNewswire/ -- Eularis is announcing the release of an update to its report, "Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line." Originally offered in February 2007, the comprehensive report has been revised to provide pharmaceutical marketers with a competitive edge and the latest research information.
*(LOGO 72dpi: Send2Press.com/mediaboom/07-0924-Eularis_72dpi.jpg)
"The pharmaceutical environment is turbulent, and what used to work to create an industry-wide growth of 20 percent, no longer does," said the author of the report, Dr. Andree K. Bates, president of Eularis. "As market growth slows, the bottom line return for brands is under increased scrutiny, and every marketing dollar must count."
Eularis identified a common problem faced by pharmaceutical companies -- how to know which activities impact market share and by how much. The company assembled a group of world-leading mathematicians in the predictive analytics field, as well as thought leaders, to find the solution.
This report, in turn, analyzes how top pharmaceutical marketing leaders are handling pressing marketing return issues, and offers new ideas to apply. The detailed research addresses issues such as: ROI basics; practical skills marketers need for measuring marketing effectiveness; tools and best practices that make a difference; measurement principles that drive successful marketing measurement; how to propel strategy, growth, and bottom line return; plus an array of case studies.
The report also explains what real people did to measure, improve, and
prove bottom line return. It uncovers practices to predict how and where
pharmaceutical marketing and sales investments will yield the highest
market share and market share price. Readers will benefit from the
step-by-step guidelines on successfully implementing approaches for real
and measurable resu
'/>"/>
| SOURCE Eularis Copyright©2007 PR Newswire. All rights reserved |